Ultragenyx Pharmaceutical Inc.
DE ˙ DB ˙ US90400D1081
19,12 € ↑0,58 (3,13%)
2026-06-04
PREZZO DELLE AZIONI
SecurityDE:UP0 / Ultragenyx Pharmaceutical Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,500,528 shares
Latest Disclosed Value $ 31,436,092
Morgan Stanley reports 17.84% decrease in ownership of UP0 / Ultragenyx Pharmaceutical Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 1,500,528 shares of Ultragenyx Pharmaceutical Inc. (DE:UP0) valued at $25,358,923 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 1,826,295 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of -17.84% during the quarter. The current value of the position is $28,682,593 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,500,528 -325,767 -17.84 31,436 -25.16 0.0019
2026-05-27 2025-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,826,295 916,112 100.65 42,005 53.42 0.0025
2026-02-13 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,826,295 916,112 42,005 0.0025
2026-05-27 2025-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 910,183 271,304 42.47 27,378 17.86 0.0017
2025-11-14 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 910,183 271,304 27,378 0.0017
2025-08-15 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 638,879 12,479 1.99 23,230 2.42 0.0015
2025-05-15 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 626,400 28,211 4.72 22,682 -9.87 0.0016
2025-05-15 2024-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 598,189 130,353 27.86 25,166 -3.17 0.0018
2025-02-14 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 598,189 130,353 25,166 0.0018
2025-05-14 2024-09-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 467,836 -30,133 -6.05 25,988 26.98 0.0019
2025-02-14 2024-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 467,836 -30,133 25,988 0.0019
2024-11-14 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 467,836 -30,133 25,988 0.0002
2025-05-14 2024-06-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 497,969 -6,413 -1.27 20,467 -13.09 0.0016
2024-10-17 2024-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 497,969 -6,413 20,467 0.0016
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 497,969 -6,413 20,467 0.0016
2024-10-17 2024-03-31 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 504,382 -93,167 -15.59 23,550 -17.59 0.0019
2024-08-16 2024-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 504,382 -93,167 23,550 0.0002
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 504,382 -93,167 23,550 0.0019
2024-08-16 2023-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 597,549 102,060 20.60 28,575 61.76 0.0025
2024-02-13 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 597,549 102,060 28,575 0.0025
2023-11-15 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 495,489 -21,686 -4.19 17,664 -25.96 0.0018
2023-08-14 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 517,175 158,765 44.30 23,857 66.00 0.0024
2023-05-15 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 358,410 50,063 16.24 14,372 0.61 0.0015
2023-02-14 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 308,347 -91,766 -22.94 14,286 -13.78 0.0016
2022-11-14 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 400,113 70,464 21.38 16,568 -15.75 0.0023
2022-10-27 2022-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 329,649 84,910 34.69 19,666 10.65 0.0026
2022-08-15 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 329,649 84,910 19,666 0.0026
2022-10-27 2022-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 244,739 52,735 27.47 17,773 10.08 0.0024
2022-05-13 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 244,739 52,735 17,773 0.0024
2022-02-14 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 192,004 -37,065 -16.18 16,146 -21.85 0.0020
2021-11-15 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 229,069 -161,029 -41.28 20,659 -44.46 0.0028
2021-08-23 2021-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 390,098 152,916 64.47 37,197 37.74 0.0049
2021-08-16 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 390,098 152,916 37,197 0.0010
2021-05-17 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 237,182 -14,146 -5.63 27,006 -22.38 0.0040
2021-02-16 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 251,328 129,855 106.90 34,791 248.47 0.0054
2020-11-13 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 121,473 27,170 28.81 9,984 35.34 0.0019
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 94,303 13,688 16.98 7,377 105.95 0.0016
2020-05-26 2020-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 80,615 -75,895 -48.49 3,582 -46.41 0.0010
2020-05-15 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 80,615 -75,895 3,582 275.1723
2020-02-14 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 156,510 16,850 12.07 6,684 11.90 0.0016
2019-11-14 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 139,660 55,492 65.93 5,973 11.75 0.0016
2019-08-14 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 84,168 61,549 272.11 5,345 240.66 0.0014
2019-05-15 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 22,619 -124,619 -84.64 1,569 -75.49 0.0004
2019-02-14 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 147,238 -3,950 -2.61 6,402 -44.53 0.0019
2019-04-23 2018-09-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 151,188 -34,247 -18.47 11,541 -19.04 0.0029
2018-11-20 2018-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 151,188 0 11,541 0.0029
2018-11-14 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 151,188 -34,247 11,541
2019-04-23 2018-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 185,435 68,812 59.00 14,255 139.70 0.0039
2018-08-14 2018-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 185,435 68,812 14,255
2019-04-23 2018-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 116,623 21,984 23.23 5,947 35.50 0.0017
2018-05-14 2018-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 116,623 21,984 5,947
2019-04-23 2017-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 94,639 11,890 14.37 4,389 -0.43 0.0012
2018-02-14 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 94,639 11,890 4,389
2017-11-14 2017-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 82,749 16,128 24.21 4,408 6.55 0.0013
2017-08-11 2017-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 66,621 -9,487 -12.47 4,137 -19.81 0.0012
2017-05-22 2017-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 76,108 -59,952 -44.06 5,159 -46.07 0.0016
2017-05-12 2017-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 76,108 5,159
2017-02-22 2016-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 136,060 86,127 172.49 9,566 170.15 0.0031
2017-02-13 2016-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 136,060 9,566
2016-11-10 2016-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 49,933 17,272 52.88 3,541 121.59 0.0012
2016-08-12 2016-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 32,661 3,469 11.88 1,598 -13.53 0.0006
2016-05-12 2016-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 29,192 -1,489 -4.85 1,848 -46.29 0.0007
2016-02-09 2015-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 30,681 -6,794 -18.13 3,441 -4.66 0.0012
2016-02-08 2015-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 37,475 -16,289 -30.30 3,609 -34.44 0.0013
2015-11-09 2015-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 37,475 3,609
2015-08-12 2015-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 53,764 -17,228 -24.27 5,505 24.89 0.0019
2015-05-14 2015-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 70,992 3,831 5.70 4,408 49.58 0.0016
2015-02-13 2014-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 67,161 -2,219 -3.20 2,947 -24.94 0.0011
2014-12-16 2014-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 69,380 -12,725 -15.50 3,926 -2.19 0.0015
2014-11-14 2014-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 69,380 3,926
2014-05-13 2014-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 82,105 82,105 4,014 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.